{
    "clinical_study": {
        "@rank": "36655", 
        "arm_group": {
            "arm_group_label": "MOR00208 (formerly Xmab5574)", 
            "arm_group_type": "Experimental", 
            "description": "intravenous Infusion of MOR00208, Fc-optimized Anti-CD19 Antibody"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, multicentre study to characterize the safety and preliminary efficacy\n      of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory B-cell\n      acute lymphoblastic leukemia (B-ALL)"
        }, 
        "brief_title": "Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Lymphoblastic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Burkitt Lymphoma", 
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with previously treated Philadelphia-chromosome-negative B-ALL, with\n             progression after at least one prior therapy. Patients with\n             Philadelphia-chromosome-positive B-ALL can only be included if they are refractory or\n             intolerant to at least one tyrosine-kinase-inhibitor.\n\n          -  Male or female patients at least  16 years of age; if the patient is less than 18\n             years of age, the patient must have the ability to understand and give written assent\n             in addition to the parent's/guardian's written informed consent.\n\n          -  Patients with histologically confirmed diagnosis of B-ALL\n\n          -  Mixed phenotype acute leukemia patients who have B cell immunophenotype.\n\n          -  Patients with an Eastern Cooperative Oncology Group performance status of less than\n             or equal to 2\n\n          -  Patients with a total bilirubin of less than or equal to 2.0 mg/dL\n\n          -  Patients with alanine aminotransferase or aspartate aminotransferase less than or\n             equal to 2.5 times the upper limit of normal\n\n          -  Patients with a creatinine level of less than or equal to 2.0 mg/dL\n\n          -  If a female of childbearing potential, confirmation of a negative pregnancy test\n             before enrollment and use of double-barrier contraception, confirmation of a negative\n             pregnancy test before enrollment and use of  oral contraceptive plus barrier\n             contraceptive, or confirmation of having undergone clinically documented total\n             hysterectomy, oophorectomy, or tubal ligation\n\n          -  If a male, use of an effective barrier method of contraception during the study and\n             for 3 months after the last dose if sexually active with a female of childbearing\n             potential\n\n          -  Patients with the ability to understand and give written informed consent and to\n             comply with the study protocol\n\n        Exclusion Criteria:\n\n          -  Patients who received previous treatment with an anti-CD19 antibody or fragments\n\n          -  Receipt of  anti-CD20 therapy no greater than  4 weeks before the first study dose\n\n          -  Patients having undergone prior allogeneic stem cell transplantation within 3 months\n             or having active graft versus host disease\n\n          -  Patients with known hypersensitivity to any excipient contained in the drug\n             formulation\n\n          -  Patients with a New York Heart Association Class III or IV\n\n          -  History of stroke or myocardial infarction within the last 6 months\n\n          -  Patients with a history of positive human immunodeficiency virus test result (ELISA\n             or western blot)\n\n          -  Patients with positive hepatitis serology. Hepatitis B (HBV): Patients with positive\n             serology for hepatitis B, defined as positive for hepatitis B surface antigen (HbsAg)\n             or total anti-hepatitis B core antibody (anti-Hbc). Patients positive for anti- Hbc\n             may be included if hepatitis B viral DNA is not detectable. Hepatitis C (HCV):\n             Patients with positive hepatitis C serology (defined as positive for anti-hepatitis C\n             virus antibody (anti-HCV) unless HCV-RNA is confirmed negative.\n\n          -  Patients with active viral, bacterial, or systemic fungal infection requiring active\n             parenteral treatment\n\n          -  Patients who are receiving active treatment/chemotherapy for another primary\n             malignancy or have received any treatment, including surgery, radiation, or\n             chemotherapy, within the past 5 years (except ductal breast cancer in situ, for\n             nonmelanoma skin cancer, prostate cancer not requiring treatment, and cervical\n             carcinoma in situ)\n\n          -  Patients who are pregnant or breastfeeding\n\n          -  Patients with major surgery or radiation therapy within 4 weeks prior to first study\n             dose"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01685021", 
            "org_study_id": "MOR208C202"
        }, 
        "intervention": {
            "arm_group_label": "MOR00208 (formerly Xmab5574)", 
            "intervention_name": "MOR00208 (formerly Xmab5574)", 
            "intervention_type": "Drug", 
            "other_name": "MOR208"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "B-ALL", 
            "CD19", 
            "MOR208", 
            "MOR00208", 
            "Xmab5574", 
            "B-cell acute lymphoblastic leukemia", 
            "Fc-optimized Anti-CD19 Antibody"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Rebecca Klisovic, MD", 
                    "phone": "614-293-2268"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43201"
                    }, 
                    "name": "Ohio State University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Rebecca Klisovic, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "info@stjude.org", 
                    "last_name": "Wing H. Leung, M.D., PhD", 
                    "phone": "866-278-5833"
                }, 
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38105"
                    }, 
                    "name": "St. Jude Children's Research Hospital"
                }, 
                "investigator": {
                    "last_name": "Wing H. Leung, M.D., PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Susan O\u00b4Brian, MD", 
                    "phone": "713-792-7543"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "University of Texas M.D. Anderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Susan O`Brian, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase IIa, Single-arm, Open-label Study of MOR00208, a Humanized Fc-Engineered Anti-CD19 Antibody, in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)", 
        "overall_contact": {
            "email": "info@morphosys.com", 
            "last_name": "Roman Korolkiewicz", 
            "phone": "+49 8989927", 
            "phone_ext": "0"
        }, 
        "overall_official": [
            {
                "affiliation": "MDA", 
                "last_name": "Susan O\u00b4Brien, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ohio State University", 
                "last_name": "Rebecca Klisovic, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "St. Jude Children's Research Hospital", 
                "last_name": "Wing H. Leung, M.D., PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "ORR= CR (Complete Remission) + PR (Partial Remission)\nAntitumor activity of MOR00208", 
            "measure": "Overall response rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "7 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01685021"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "1. Patients response duration evaluation by hematology, bone marrow aspirates or biopsy, CT", 
                "safety_issue": "No", 
                "time_frame": "weekly, up to 7 months"
            }, 
            {
                "measure": "2. Safety will be evaluated by assessing adverse events, clinical lab data and vital signs, ECG, physical exam", 
                "safety_issue": "Yes", 
                "time_frame": "weekly, up to 7 months"
            }, 
            {
                "measure": "3. Pharmacokinetics of MOR00208 (Pharmacokinetic assessment comprises: Cmax, tmax, t 1/2, CL)", 
                "safety_issue": "No", 
                "time_frame": "weekly, up to 16 weeks"
            }, 
            {
                "measure": "4. Number of patients who develop ant-MOR00208 antibodies as a measure of immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "monthly, up to 7 months"
            }
        ], 
        "source": "MorphoSys AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MorphoSys AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}